Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive phase III tofacitinib data

Pfizer reports positive phase III tofacitinib data

3rd May 2011

Pfizer has published clinical trial data that highlights the benefits of its investigational drug tofacitinib in treating rheumatoid arthritis.

Top-line results from the 12-month Oral Standard trial showed that signs of symptoms of the disease were reduced among patients who had previously an inadequate response to methotrexate, while the drug also delivered improvement in physical function.

Meanwhile, data from another phase III study, Oral Step, delivered similarly positive results among those who had been unable to benefit from treatment with TNF inhibitors.

It meant that the compound was able to meet its primary efficacy endpoints in both studies, while its safety performance was consistent with data collated from previous trials.

Pfizer stated that it will provide a more detailed analysis of the trial data from Oral Standard and Oral Step at a future scientific meeting.

This comes after a separate tofacitinib trial, Oral Scan, yielded further positive results that Pfizer reported last month.ADNFCR-8000103-ID-800516629-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.